14 Result(s)

Article

Fresh or frozen grafts for allogeneic stem cell transplantation: conceptual considerations and a survey on the practice during the COVID-19 pandemic from the EBMT Infectious Diseases Working Party (IDWP) and Cellular Therapy & Immunobiology Working Party (CTIWP)

The COVID-19 pandemic has had a significant impact on medical practices, including the delivery of allogeneic hematopoietic cell transplantation (HCT). In response, transplant centers have made changes to thei...

N. Worel, P. Ljungman, I. C. M. Verheggen, J. D. Hoogenboom… in Bone Marrow Transplantation (2023)

Article

Multi-color immune-phenoty** of CD34 subsets reveals unexpected differences between various stem cell sources

Flow cytometric routine CD34 analysis enumerates hematopoietic stem and progenitor cells irrespective of their subpopulations although this might predict engraftment dynamics and immune reconstitution. We esta...

J Dmytrus, S Matthes-Martin, H Pichler, N Worel… in Bone Marrow Transplantation (2016)

Article

Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party

Little is known about the prognostic impact of prior paclitaxel therapy and response to induction chemotherapy defined as the regimen preceding high-dose chemotherapy (HDCT) for the salvage therapy of advanced...

A Necchi, R Miceli, M Bregni, C Bokemeyer, L A Berger… in Bone Marrow Transplantation (2016)

Article

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation

Autologous haematopoietic SCT with PBSCs is regularly used to restore BM function in patients with multiple myeloma or lymphoma after myeloablative chemotherapy. Twenty-eight experts from the European Group fo...

M Mohty, K Hübel, N Kröger, M Aljurf, J Apperley, G W Basak… in Bone Marrow Transplantation (2014)

Article

Allogeneic hematopoietic stem cell donation—standardized assessment of donor outcome data: A consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT)

The number of allogeneic hematopoietic SCTs performed globally each year continues to increase, paralleled by an increased demand for donors of therapeutic cells. Donor characteristics and collection procedure...

J P Halter, S M van Walraven, N Worel, M Bengtsson… in Bone Marrow Transplantation (2013)

Article

European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization

The effectiveness of the novel hematopoietic stem cell mobilizing agent plerixafor was evaluated in nationwide compassionate use programs in 13 European countries. A total of 580 poor mobilizers with non-Hodgk...

K Hübel, M M Fresen, J F Apperley, G W Basak, K W Douglas… in Bone Marrow Transplantation (2012)

Article

Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF

G W Basak, W Wiktor-Jedrzejczak, J F Apperley, K W Douglas… in Bone Marrow Transplantation (2012)

Article

Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA

We describe 20 patients with myeloma and 1 with primary amyloidosis from 15 centres, all with advanced renal failure, most of whom had PBSC mobilised using plerixafor following previous failed mobilisation by ...

K W Douglas, A N Parker, P J Hayden, A Rahemtulla, A D'Addio… in Bone Marrow Transplantation (2012)

Article

The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF

We report 13 multiple myeloma (MM) or lymphoma patients who were failing PBSC mobilization after disease-specific chemotherapy and granulocyte-CSF (G-CSF), and received plerixafor to successfully collect PBSCs...

A D'Addio, A Curti, N Worel, K Douglas, M R Motta, S Rizzi… in Bone Marrow Transplantation (2011)

Article

Regeneration, health status and quality of life after rhG-CSF-stimulated stem cell collection in healthy donors: a cross-sectional study

Mobilized allogeneic PBPC are increasingly used instead of BM for allogeneic stem cell grafting. Although the short-term safety profile of recombinant human (rh)G-CSF seems acceptable, only minimal data on lon...

G C Leitner, K Baumgartner, P Kalhs, D Biener, H T Greinix… in Bone Marrow Transplantation (2009)

Article

Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb^® immunoadsorption

Delayed donor red cell engraftment and prolonged red cell aplasia (PRCA) are well-recognized complications of major ABO-incompatible myeloablative and nonmyelo-ablative hematopoietic stem cell transplantation ...

W Rabitsch, P Knöbl, E Prinz, F Keil, H Greinix, P Kalhs… in Bone Marrow Transplantation (2003)

Article

Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation

We assessed long-term outcome in 155 patients who had undergone an allogeneic/syngeneic stem cell transplant (SCT) and were in complete remission for more than 2 years after transplant. Probability of late tra...

N Worel, D Biener, P Kalhs, M Mitterbauer, F Keil… in Bone Marrow Transplantation (2002)

Article

Immunologic recovery of patients given CD34-selected peripheral blood progenitor cell transplantation for malignant diseases

A Schulenburg, P Kalhs, N Worel, P Höcker, P Knöbl… in Bone Marrow Transplantation (2000)